In 2015, sirolimus became the first drug approved by the US FDA for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive, cystic lung disease associated with inappropriate activation of mTOR signaling [11,12,13]. Here, MTOR is linked to lymphangioleiomyomatosis.